Cardiovascular disease in rheumatoid arthritis. Importance and clinical management;Enfermedad cardiovascular en artritis reumatoide. Importancia y tratamiento clínico

Reumatologia Clinica

Volumn 5, Issue 3, 2009, Pages 95-97

  González Gay, Miguel A ^a   González Juanatey, Carlos ^a  

^a HOSPITAL XERAL CALDE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; ATHEROMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; HUMAN; PHYSICAL ACTIVITY; RHEUMATOID ARTHRITIS;

EID: 65049087016     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2009.01.001     Document Type: Article

References (31)

1. Goodson N., Marks J., Lunt M., and Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 64 (2005) 1595-1601
2. Solomon D.H., Karlson E.W., Rimm E.B., Cannuscio C.C., Mandl L.A., Manson J.E., et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107 (2003) 1303-1307
3. González-Gay M., González-Juanatey C., and Martin J. Rheumatoid arthritis: A disease associated with accelerated atherogenesis. Semin Arthritis Rheum 35 (2005) 8-17
4. Del Rincón I., Williams K., Stern M.P., Freeman G.L., and Escalante A. High incidence of cardiovascular events in rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44 (2001) 2737-2745
5. González-Gay M.A., González-Juanatey C., López-Díaz M.J., Piñeiro A., García-Porrua C., Miranda-Filloy J.A., et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 57 (2007) 125-132
6. Nicola P.J., Maradit-Kremers H., Roger V.L., Jacobsen S.J., Crowson C.S., Ballman K.V., et al. The risk of congestive heart failure in rheumatoid arthritis: A population-based study over 46 years. Arthritis Rheum 52 (2005) 412-420
7. González-Gay M.A., González-Juanatey C., Vázquez-Rodríguez T.R., Martin J., and Llorca J. Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis. Semin Arthritis Rheum 38 (2008) 67-70
8. González-Juanatey C., Testa A., García-Castelo A., García-Porrúa C., Llorca J., Ollier W.E., et al. Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 33 (2004) 231-238
9. González-Gay M.A., González-Juanatey C., and Martin J. Inflammation and endothelial dysfunction in rheumatoid arthritis. Clin Exp Rheumatol 24 (2006) 115-117
10. González-Juanatey C., Testa A., García-Castelo A., García-Porrúa C., Llorca J., Vidan J., et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 114 (2003) 647-652
11. Vaudo G., Marchesi S., Gerli R., Allegrucci R., Giordano A., Siepi D., et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 63 (2004) 31-35
12. González-Juanatey C., Llorca J., Testa A., Revuelta J., García-Porrua C., and González-Gay M.A. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 82 (2003) 407-413
13. González-Gay M.A., González-Juanatey C., Piñeiro A., García-Porrua C., Testa A., and Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 32 (2005) 1219-1223
14. González-Juanatey C, Llorca J, Martin J, González-Gay M.A. Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2008 Mar 11. [En prensa].
15. Krishnan E., Lingala V.B., and Singh G. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation 110 (2004) 1774-1779
16. Krause D., Schleusser B., Herborn G., and Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 43 (2000) 14-21
17. Choi H.K., Hernan M.A., Seeger J.D., Robins J.M., and Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet 359 (2002) 1173-1177
18. Carmona L., Descalzo M.A., Pérez-Pampin E., Ruiz-Montesinos D., Erra A., Cobo T., et al., BIOBADASER and EMECAR Groups. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 66 (2007) 880-885
19. Hürlimann D., Forster A., Noll G., Enseleit F., Chenevard R., Distler O., et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106 (2002) 2184-2187
20. González-Juanatey C., Testa A., García-Castelo A., García-Porrua C., Llorca J., and González-Gay M.A. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 51 (2004) 447-450
21. González-Juanatey C., Llorca J., Sánchez-Andrade A., García-Porrua C., Martin J., and González-Gay M.A. Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 24 (2006) 309-312
22. González-Juanatey C., Llorca J., Vázquez-Rodríguez T.R., Díaz-Varela N., García-Quiroga H., and González-Gay M.A. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 59 (2008) 1821-1824
23. González-Juanatey C., Llorca J., García-Porrua C., Martin J., and González-Gay M.A. Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum 55 (2006) 150-153
24. Del Porto F., Laganà B., Lai S., Nofroni I., Tinti F., Vitale M., et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 46 (2007) 1111-1115
25. McCarey D.W., McInnes I.B., Madhok R., Hampson R., Scherbakov O., Ford I., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): Double-blind, randomised placebo-controlled trial. Lancet 363 (2004) 2015-2021
26. Hermann F., Forster A., Chenevard R., Enseleit F., Hürlimann D., Corti R., et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol 45 (2005) 461-464
27. Gil-Guillén V., Orozco-Beltrán D., Maiques-Galán A., Aznar-Vicente J., Navarro J., Cea-Calvo L., et al. Agreement between REGICOR and SCORE scales in identifying high cardiovascular risk in the Spanish population. Rev Esp Cardiol 60 (2007) 1042-1050
28. Van Halm V.P, Peters M.J, Voskuyl A.E, Boers M, Lems W.F, Dijkmans B, et al. Rheumatoid arthritis versus type 2 diabetes as a risk factor for cardiovascular disease, a cross-sectional study. The CARRE Investigation. Ann Rheum Dis. 2008 Aug 12 [En prensa].
29. Sihvonen S., Korpela M., Mustila A., and Mustonen J. The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis. J Rheumatol 32 (2005) 2089-2094
30. Snir O, Widhe M, Von Spee C, Lindberg J, Padyukov L, Lundberg K, et al. Multiple antibody reactivities to citrullinated antigens in sera from rheumatoid arthritis patients-association with HLA-DRB1 alleles. Ann Rheum Dis. 2008 Jul 17. [En prensa].
31. Peters M.J, Symmons D, McCarey D, Dijkmans B.A, González-Gay M.A, Kitas G, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis: Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. En prensa 2009.